Vrije Universiteit Brussel



GOA78 (2011-2015)


Nair N, Rincon M., Evens H, Sarkar S, Dastidar, S., Samara-Kuko E, Ghandeharian O, Viecelli HM, Beat Thöny B, De Bleser P, VandenDriessche T, Chuah MK. Computationally designed liver-specific transcriptional cis-regulatory modules and hyperfunctional factor IX improve liver-targeted gene therapy for hemophilia B., Blood, in press.

Chuah, M., Nair, N., VandenDriessche, T. Gene therapy for hemophilia A and B. Gene therapy for hemophilia A and B. Advanced Textbook on Gene transfer, Gene Therapy and Genetic Pharmacology. Ed. D. Sherman. Imperial College, 2014.

Di Matteo M., Samara-Kuko E., Chuah MK, VandenDriessche T. Hyperactive piggyBac transposons for sustained and robust liver-targeted gene therapy of hemophilia B. Mol. Ther, 2014, minor revision.

Chuah, M., Petrus, I., De Bleser P., Le Guiner, C., Gernoux, G., Adjali, O., Nair, N., Willems, J., Evens, H., Rincon, M., Matrai, J., Di Matteo, M., Samara-Kuko, E., Yan, B., Acosta-Sanchez, A., Meliani, A., Cherel, G., Blouin, V., Christophe, O., Moullier, P., Mingozzi, F., VandenDriessche, T. Liver targeting in mice and primates using hepatocyte-specific transcriptional modules identified by genome-wide in silico analysis Hepatology, submitted (2014).


Maes K, De Smedt E, Lemaire M, De Raeve H, Menu E, Van Valckenborgh E, McClue S, Vanderkerken K and De Bruyne E. The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma. Submitted on 22nd of January 2013.

Maes K, Menu E, Van Valckenborgh E, Van Riet I, Vanderkerken K and De Bruyne E. Epigenetic modulating agents as a new therapeutic approach in multiple myeloma. Cancers,2013,5:430-61.

De Bruyne E, Maes K, Deleu S, Van Valckenborgh E, Menu E, Vande Broek I, van Grunsven L, Rogiers V, Jernberg-Wiklund H and Vanderkerken K. Epigenetic regulation of multiple myeloma within its bone marrow microenvironment. Advances in biology and therapy of multiple myeloma, Springer, 2013, 1: 255-82.

Bolleyn J., De Kock J., Mertens H., Fraczek J., Vinken M., Govaere O., Roskams T., Rogiers V., Vanhaecke T. (2013) Liver-Specific miR-122 dos not affect mRNA levels of Cytochrome P450 enzymes and nuclear receptors in primary rat hepatocyte cultures. ALTEX-Alternatives to Animal Experimentation 29:165-172.

Fraczek J., Bolleyn J., Vanhaecke T., Rogiers V., Vinken M. (2013) Primary hepatocyte cultures for pharmaco-toxicological studies: at the busy crossroad of various antidedifferentiation strategies. Archives of Toxicology 87(4): 577-610.

Fraczek J., Vanhaecke T., Rogiers V. (2013) Toxicological and Metabolic Considerations for HDAC inhibitors. Expert Opinion on Drug Metabolism and Toxicology 9(4): 441-457.

Godoy P., Hewitt N.J., Albrecht U., Andersen M.E., Ansari N., Bhattacharya S., Bode J.G., Bolleyn J., Borner C., Böttger J., Braeuning A., Budinsky R.A., Burkhardt B., Cameron N.R., Camussi G., Cho C.S., Choi Y.J., Craig Rowlands J., Dahmen U., Damm G., Dirsch O., Donato M.T., Dong J., Dooley S., Drasdo D., Eakins R., Ferreira K.S., Fonsato V., Fraczek J., Gebhardt R., Gibson A., Glanemann M., Goldring C.E., Gómez-Lechón M.J., Groothuis G.M., Gustavsson L., Guyot C., Hallifax D., Hammad S., Hayward A., Häussinger D., Hellerbrand C., Hewitt P., Hoehme S., Holzhütter H.G., Houston J.B., Hrach J., Ito K., Jaeschke H., Keitel V., Kelm J.M., Kevin Park B., Kordes C., Kullak-Ublick G.A., LeCluyse E.L., Lu P., Luebke-Wheeler J., Lutz A., Maltman D.J., Matz-Soja M., McMullen P., Merfort I., Messner S., Meyer C., Mwinyi J., Naisbitt D.J., Nussler A.K., Olinga P., Pampaloni F., Pi J., Pluta L., Przyborski S.A., Ramachandran A., Rogiers V., Rowe C., Schelcher C., Schmich K., Schwarz M., Singh B., Stelzer E.H., Stieger B., Stöber R., Sugiyama Y., Tetta C., Thasler W.E., Vanhaecke T., Vinken M., Weiss T.S., Widera A., Woods C.G., Xu J.J., Yarborough K.M., Hengstler J.G. (2013) Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Archives of Toxicology 87(8):1315-530.

Mannaerts, I., Schroyen B., Verhulst S., Van Lommel L., Schuit F., Nyssen M., van Grunsven LA. Gene Expression Profiling of Early Hepatic Stellate Cell Activation Reveals a Role for Igfbp3 in Cell Migration. PLoS ONE, 2013. 8(12): p. e84071.

Mannaerts I, Eysackers N, Onyema OO, Van Beneden K, Valente S, Mai A, Odenthal M, van Grunsven LA. Class II HDAC inhibition hampers hepatic stellate cell activation by induction of microRNA-29. PLoS One. 2013;8(1):e55786. Epub 2013 Jan 31.

Van Beneden K, Mannaerts I, Pauwels M, Van den Branden C, van Grunsven LA. HDAC inhibitors in experimental liver and kidney fibrosis. Fibrogenesis Tissue Repair. 2013 Jan 2;6(1):1.


Cantore, A., Nair, N., Della Valle, P.*, Di Matteo, M., Màtrai, J., Sanvito, F., Brombin, C., Di Serio, C., D’Angelo, A., Chuah, M.K., Naldini, L. and VandenDriessche, T. Hyper-functional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice. Blood 120(23):4517-20 (2012) + Commentary: Lozier JN. Factor IX Padua: them that have, give. Blood 120(23):4452-3 (2012).

Di Matteo, M., Belay, E., Chuah, M.K., VandenDriessche, T. Recent developments in transposon-mediated gene therapy. Exp. Opin. Biol. Ther., 12(7):841-58 (2012).

Di Matteo, M., Mátrai, J., Belay, E., Firdissa, T., VandenDriessche, T., Chuah, M.K. PiggyBac Toolbox. Methods Mol Biol. 859:241-54 (2012).

Chuah, M.K., Nair, N., VandenDriessche, T., Recent progress in gene therapy for haemophilia. Hum. Gene Ther., 23(6):557-65 (2012).

Lemaire M, Fristedt C, Agarwal P, Menu E, Van Valckenborgh E, De Bruyne E, Atadja P, Van Camp B, Jernberg-Wiklund H, Vanderkerken K. The HDAC inhibitor LBH589 enhances the anti-myeloma effect of the IGF-1 RTK inhibitor picropodophyllin. Clinical Cancer Research, 2012,18:2230-9. (IP: 7,837)

Doktorova T.Y., Ellinger-Ziegelbauer H., Vinken M., Vanhaecke T., van Delft J., Kleinjans J., Ahr H.J., Rogiers V. (2012) Comparison of genotoxicant-modified transcriptomic responses in conventional and epienetically-stabilized primary rat hepatocytes with in vivo rat liver data. Archives of Toxicology 86(11): 703-1715.

Fraczek J., Vinken M., Tourwé D., Vanhaecke T., Rogiers V. (2012) Synergetic effect of DNA demethylation and histone deacetylase inhibition in primary rat hepatocytes. Investigational New Drugs, 30(4): 1715-1724


Mátrai, J.,bCantore, A., Bartholomae, C., Annoni, A.,Wang, W., Acosta-Sanchez, A., Samara-Kuko, E., De Waele, L., Ma, L., Genovese, P., von Kalle, C., Chuah, M.K., Roncarolo, M.G., Schmidt, M., VandenDriessche, T., Naldini, L. Hepatocyte-targeted Expression by Integrase-Defective Lentiviral Vectors Induces Transgene-specific Immune Tolerance With Low Genotoxic Risk. Hepatology 53(5):1696-707 (2011)

Bolleyn J., Fraczek J., Vinken M., Lizaraga D., Gaj S., Joost H.M., van Delft J., Rogiers V. and Vanhaecke T. (2011) Effect of Trichostatin A on miRNA expression in primary rat hepatocytes. Toxicology in Vitro 25: 1173-1182.

Henkens T., Snykers S.,* Vinken M., Fraczek J., Lukaszuk A., Tourwé D., Verheyen G., Van Gompel J.V., Vanparys P., Rogiers V., Vanhaecke T. (2011) Preservation of hepatocellular functionality in cultures of primary rat hepatocytes upon explosure to 4-Me(2)N-BAVAH, a hydroxamate-based HDAC-inhibitor. Toxicology in Vitro 25(1): 100-109. *Equal contribution

GOA48 (2006-2010)

De Bruyne E, Bos T, Asosingh K, Vande Broek I, Menu E, Van Valckenborgh E, Atadja P, Coiteux V, Leleu X, Thielemans K, Van Camp B, Vanderkerken K*, Van Riet I* (* both authors contributed equally). Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survival. Clin Cancer Res. 2008 May 15;14(10):2918-26

Fraczek J, Deleu S, Lukaszuk A, Doktorova T, Tourwé D, Geerts A, Vanhaecke T, Vanderkerken K, Rogiers V. Screening of amide analogues of Trichostatin A in cultures of primary rat hepatocytes: search for potent and safe HDAC inhibitors. Invest New Drugs 2009 Aug;27(4):338-46. Epub 2008 Sep 30

Deleu S, Fraczek J, Lukaszuk A, Doktorova TY, Tourwe D, Geerts A, Van Camp B, Vanhaecke T, Rogiers V, Vanderkerken K. Screening of Trichostin analogues based on cellular potency in the murine multiple 5T33MM model. Journal of Cancer Molecules. 2008;4(4):117-121.

Deleu S, Lemaire M, Arts J, Menu E, Van Valckenborgh E, King P, Vande Broek I, De Raeve H, Van Camp B, Croucher P, Vanderkerken K. The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models.
Leukemia. 2009 Jun 4. [Epub ahead of print]

Deleu S, Lemaire M, Arts J, Menu E, Van Valckenborgh E, Vande Broek I, De Raeve H, Coulton L, Van Camp B, Croucher P, Vanderkerken K. Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma. Cancer Res. 2009 Jul 1;69(13):5307-11.

Fraczek J, van Grunsven L, Vinken M, Snykers S, Deleu S, Vanderkerken K, Vanhaecke T, Rogiers V. Histone deacetylase inhibition and the regulation of cell growth with particular reference to liver pathobiology (2009), In press, Journal of Cellular and Molecular Medicine

De Bruyne E, Bos TJ, Schuit F, Van Valckenborgh E, Menu E, Thorrez L, Atadja P, Jernberg-Wiklund H, Vanderkerken K. IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms.Blood. 2010 Jan 19. [Epub ahead of print] - PDF

Mannaerts I., Nuytten N.R., Rogiers V., Vanderkerken K., van Grunsven L.A. and Geerts A. Chronic administration of valproic acid inhibits activation of mouse hepatic stellate cells in vitro and in vivo. Hepatology 2010 Feb;51(2):603-14 - PDF


Back to top

©2006 - 2012 • FAFY/IMMI/CYTO-LIVR • Vrije Universiteit Brussel • Faculteit Geneeskunde & Farmacie • Laarbeeklaan 103 • 1090 Jette • Tel.: 02/477.44.09 • jmlazou@vub.ac.be